Athira Pays Price as Alzheimer’s Candidate Fails Trial

Athira Pharma’s experimental Alzheimer’s treatment, fosgonimeton, failed the phase II an III clinical trials, causing the company’s shares to drop 81%. The company said it would continue to develop the drug despite the failed trials. It added that in subgroups characterised by more rapid disease progression like patients with moderate Alzheimer’s, their conditions improved or stabilised after taking the drug.